



A V E X A



CAPITAL RAISING PRESENTATION

1-for-1 Non-renounceable Rights Issue

**July
2016**

**TALI: A BREAKTHROUGH
IN EARLY ASSESSMENT
AND INTERVENTION**



DISCLAIMER

This presentation is provided by Avexa Limited (**Avexa**) to provide summary information about Avexa and its subsidiaries (the **Group**). Statements in this presentation are made only as at 27 July 2016 and the information in this presentation remains subject to change without notice. The information in this presentation is of a general nature and does not purport to be complete, is provided solely for information purposes and should not be relied upon by the recipient.

This presentation is not, and does not constitute, or form any part of, an offer to sell or issue, or the solicitation, invitation or recommendation to purchase any securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. This presentation does not purport to summarise all information that a recipient should consider when making an investment decision, and should not form the basis of any decision by a recipient.

Recipients should carry out their own investigations and analysis of the Group and verify the accuracy, reliability and completeness of the information contained in this presentation or any other form of communication to which the recipient is permitted access in the course of evaluating an investment in Avexa.

No liability

To the maximum extent permitted by law, neither Avexa nor its affiliates or related bodies corporate or any of its officers, directors, employees and agents (**Related Parties**), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning, the content of this presentation, Avexa securities including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

Eligible recipients

This presentation is provided to you as an investor to whom an offer document is not required to be given. In accepting this presentation you warrant that you are an investor within the scope of this paragraph and that you accept this presentation on the basis set out in this notice. This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. This presentation may not be distributed or released in the United States. Securities may not be offered or sold in the United States statements. Each institution or person that reviews this presentation will be deemed to represent that each such institution or person is not in the United States. The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should unless such securities are registered under the U.S. Securities Act of 1933, as amended (**U.S. Securities Act**) or in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities laws. Any public offering of securities in the United States would be made by means of a prospectus that would be obtained from the issuer or selling security holder and that would contain detailed information regarding the company and management, as well as financial seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Not financial product advice

Reliance should not be placed on the information or opinions contained in this presentation. This presentation is for informational purposes only and is not a financial product or investment advice or recommendation to acquire Avexa securities and does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. You should make your own assessment of an investment in Avexa and should not rely on this presentation. In all cases, you should conduct your own research of Avexa and analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of Avexa and its business, and the contents of this presentation. You should seek legal, financial, tax and other advice appropriate to your jurisdiction.

Future performance

This presentation contains certain forward-looking statements with respect to the financial condition, operations and business of the Group and certain plans and objectives of the management of Avexa. Forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, the terms "believes", "estimates", "anticipates", "expects", "predicts", "intends", "plans", "goals", "targets", "aims", "outlook", "guidance", "forecasts", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Such forward looking statements involve known and unknown risks, uncertainties and other factors which because of their nature may cause the actual results or performance of the Group to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the political and economic environment in which the Group will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts. Forward-looking statements speak only as at the date of this presentation and to the full extent permitted by law, Avexa and its affiliates and related bodies corporate and each of its Related Parties and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

No Prospectus

This Investor Presentation is not a Product Disclosure Statement or Prospectus; it has not been lodged with ASIC; and is not regulated by Chapter 6D or Part 7.9 of the Corporations Act.



AVEXA



ABOUT AVEXA AND TALI HEALTH

COMPANY OVERVIEW



Avexa Limited (ASX: AVX) is a medical technology company revolutionising the assessment and treatment of attention difficulties

Corporate Overview

- TALI Health acquisition completed in February 2016.
- TALI's mission is to become a pioneer and leader in the assessment and treatment of childhood attention difficulties.
- The TALI System™ is a touchscreen computerised platform to profile and improve attention skills in childhood.
- TALI is expected to be in revenue at the end of 2016.
- The product will be distributed as a prescribed intervention through an established network of early childhood service providers.
- Medical claims underpinned by completed clinical trials.
- Scientific Advisory Board led by world renowned Professor Kim Cornish.
- Board, management and associates are aligned with shareholders through their combined c.11.6% shareholding.

Financial Information

Share price (22-July-16)	A\$0.035
Number of Shares	100.5m
Market capitalisation	A\$3.5m
Cash (30-June-16)	\$0.4m
Debt (30-June-16)	0
Number of Shareholders	7,489

Top Shareholders

	Shares	%
Grey Innovation Holdings	8.5m	8.5%
Megabay Holdings	7.7m	7.7%
Jonathan Lim	7.7m	7.6%
Moonah Capital	4.0m	4.0%
Sceeta Healthcare	3.0m	3.0%
Board & Management	3.1m	3.1%


THE TECHNOLOGY



AVEXA LIMITED'S LEAD PRODUCT IS THE TALI TECHNOLOGY

THE TALI TECHNOLOGY

- TALI is a breakthrough system delivered on a touchscreen computerised platform and proven to assess and improve childhood attention.
- Based on 20 years of peer reviewed research and scientifically validated in a 'gold standard' randomised control trial, TALI is proven to improve attention in childhood by focusing on strengthening and profiling underlying attentional processes.
- TALI uses the latest technology to deliver health care into the home and classroom providing significant cost savings and better outcomes for children.
- TALI provides clinicians and parents with instant access to the child's progress via the TALI web portal. Deeper analytics allow the identification of individual strengths and weaknesses allowing a more tailored approach.



Each task lasts 4 minutes

Children can select a guide

TALI is adaptive to the skill of the child


THE SCIENCE



THE TALI TECHNOLOGY WAS ASSESSED IN A CLINICAL TRIAL CONDUCTED BY MONASH UNIVERSITY



THE TRIAL

- A double-blind randomised controlled trial of 76 children with intellectual and developmental disabilities was conducted to evaluate TALI.



THE RESULTS

- TALI promoted greater improvements in attention when compared to the control group. These improvements were maintained 3 months after using TALI.
- TALI also promoted significantly greater improvements in numeracy skills compared to the control program.
- These results have been published in highly regarded peer-reviewed journals such as the *Journal of Child Psychology and Psychiatry*, and *Developmental Science*.




THE NEED & MARKET



CHILDHOOD ATTENTION DIFFICULTIES HAVE DETRIMENTAL SHORT AND LONG TERM EFFECTS

The Problem

- Childhood attention difficulties have a lifelong impact on education, mental health, social skills, employment opportunities and relationships.
- In Australia around 10% of children (approx. 400,000) have critical attention difficulties. Globally around 11% of children (approx. 6.4 million) have attention difficulties.
- Children with developmental disorders, such as autism spectrum disorder, are particularly vulnerable to attention deficits. In the US alone, 1 in 6 children between the ages of 3 to 17 years have a developmental disorder.
- A family who cares for a child with a developmental disorder faces many challenges. The physical, emotional and time cost of caring can impact the whole family, affecting relationships and physical or emotional well-being.
- Early identification and intervention is key to improving the outcomes of children with attention difficulties, as well as reducing the need for costly interventions over time.



THE CUSTOMERS



AVEXA



AVEXA IS ENGAGED WITH HEALTHCARE SERVICE PROVIDERS IN AUSTRALIA

Clinicians & Educators

- In Australia there are around 7,335 registered practices that focus on assessing and improving attention in childhood.
- In addition there are a total of 9,889 pre-school providers in Australia.
- TALI will be licensed to clinicians, educators and other service providers to be used with their clients.
- With the upcoming rollout of the National Disability Insurance Scheme (NDIS), TALI will be made available to all NDIS service providers and will be reimbursable under the Early Childhood System.

Current Clinics Engaged with TALI Health

LISTEN AND LEARN
centre

Listen and Learn Centre – Balwyn, Victoria, Australia.



Learn Quick Smart – Moonee Ponds, Victoria, Australia.



Learning Enrichment Studios – Malvern, Victoria, Australia.



Brain and Language Connections – Hawthorn East, Victoria, Australia.

Train Your Brain – Footscray, Victoria, Australia.



AVEXA



USE OF PROCEEDS



USE OF PROCEEDS

The proceeds raised from the Offer will be used to:

- Complete first commercial release version of the TALI Technology including games enhancements, development of a clinician/educator web portal and design revisions from engaged clinics' feedback;
- Conduct ongoing clinical trials to strengthen the claims of the TALI technology;
- Launch and roll-out the first versions of TALI;
- Relieve the market perception of the capital risk within Avexa;
- Corporate overheads.



AVEXA



INVESTMENT HIGHLIGHTS & RIGHTS ISSUE OFFER SUMMARY

INVESTMENT HIGHLIGHTS



A V E X A



- Our mission is to become a pioneer and a leader in the assessment and treatment of childhood attention difficulties.
- Attention difficulties are common in childhood. Around 400,000 Australian children have attention difficulties that put them at risk of long term developmental and academic issues. Children with developmental disorders are particularly vulnerable to attention difficulties.
- Australian statistics show that 28,794 school aged children are diagnosed with an autism spectrum disorder (ASD; 1%), 195,796 with Attention Deficit Hyperactivity Disorder (ADHD; 6.8%) and 287,940 with a learning disability (LD; 10%).
- TALI is a ground-breaking program designed by leading scientists to alleviate and assess childhood attention difficulties.
- TALI Health's two-part assessment and training program is designed to identify and then assist children with developmental disorder - including ASD, Down Syndrome & ADHD – in improving their attention, learning capacity and academic skills.

INVESTMENT HIGHLIGHTS



A V E X A



- The TALI technology was developed by Monash University in conjunction with Grey Innovation and Torus Games.
- **TALI Train™** - a game based training program which enhances attention skills, such as the ability to attend to relevant information, filter out distractors and inhibit impulsive responding. All training exercises are designed based on over 20 years of experience from leaders in the field of developmental psychology and in excess of 100 published research articles.
- **TALI Detect™** - a game based objective measure of attention. The back end of the TALI Train™ program, TALI Detect™ will help healthcare professionals make more accurate identifications of clinical attention deficits in young children (3 to 6 years) as well as monitoring long-term changes in attention over time.
- TALI has undertaken regulatory compliance and the process has been demonstrated under clinical trial regime.
- 5 clinics are currently trialling the TALI Technology (beta version).
- Discussions in progress with another 50 centres across Australia and internationally.
- First revenues expected from initial commercial roll out in Q4 2016.



SUMMARY OF RIGHTS ISSUE

A summary of the key information in respect of the Rights Issue is shown in the table below. Shareholders should read the Information Booklet in its entirety before deciding to participate in the Rights Issue.

Ratio:	One New Share for every one existing ordinary Share (Non-renounceable)
Issue Price:	\$0.022 per share
Number of New Shares:	100,459,182
Gross Proceeds:	\$2,210,102 (If fully subscribed)
Underwriter:	InterPrac Financial Planning Pty Ltd
Underwriting Amount:	82 million shares will be underwritten at \$0.022 per share totalling \$1,804,000.

Underwriter contact details:

Garry Crole | Managing Director | InterPrac Financial Planning Pty Ltd
Level 3, 29-33 Palmerston Crescent | South Melbourne | Vic 3205

P: 03 9209 9770 F: 03 9209 9770 E: garry.crole@interprac.com.au



SUMMARY OF RIGHTS ISSUE



A V E X A



KEY DATES (INDICATIVE)

27 July 2016	Announcement Date Appendix 3B lodged with ASX
3 August 2016	Ex Date
4 August 2016	Record Date
9 August 2016	Dispatch of offer documents Rights Issue opens
23 August 2016	Rights Issue Closing Date
26 August 2016	Shortfall Notification Date
29 August 2016	Settlement Date



Board and Management

- Iain Kirkwood, Chairman
- Jefferson Harcourt, Non-executive Director
- Mark Simari, Non-executive Director *(will be appointed at the conclusion of the Right Issue Offer)*
- Allan Tan, Non-executive Director *(will not be seeking re-election at the 2016 AGM)*

-
- Professor Kim Cornish, Chair, Scientific Advisory Board
 - Dr Hannah Kirk, Chief Research Officer

-
- Lee Mitchell, Company Secretary
 - Magda Klapakis, Financial Controller



Scientific Advisory Board



Professor Kim Cornish
Chair of the TALI Scientific Advisory Board

Professor Cornish is the Head of School of Psychological Sciences and Deputy Dean of the Faculty of Biomedical and Psychological Sciences at Monash University. She is also the Director of the Monash Institute of Clinical and Cognitive Neurosciences. Previously, she was the Canadian Research Chair in Developmental Neuroscience and Professor at McGill University. She currently retains an Adjunct Professorship in the Department of Neurology & Neurosurgery at the Montréal Neurological Institute and is special professor in the Division of Developmental Psychiatry at Nottingham University in the UK. Professor Cornish is recognised internationally for her work in the field of neurodevelopmental disorders, genetics and atypical cognitive pathways, particularly attention related atypicalities.



Professor Mark Bellgrove
Cognitive Neuroscientist, Monash University (AUS)

Professor Bellgrove is a cognitive neuroscientist in the School of Psychological Sciences at Monash University in Australia. He is currently Chair of Research Strategy in the School of Psychological Sciences at Monash University. He undertook his post-doctoral training at the Institute of Neuroscience at Trinity College in the UK. He returned to Australia and the University of Melbourne under a prestigious NHMRC Howard Florey Centenary Fellowship. He later relocated to the Queensland Brain Institute at the University of Queensland as part of an initiative to develop cognitive neuroscience at this institution. Professor Bellgrove has been awarded an NHMRC Career Development Award (Level 2), multiple NHMRC and ARC project grants and Future Fellowship (Level 3) from the Australian Research Council. His research focuses on the biological basis of attention and uses state-of-the-art cognitive neuroscience suites alongside molecular facilities for functional genomics.




Professor Gaia Scerif
Developmental Neuroscientist, Oxford University (UK)

Professor Scerif is a developmental neuroscientist at Oxford University in the UK. Previously she worked as a visiting fellow at the Sackler Institute of Developmental Psychobiology at Cornell University in the USA, and a lecturer in the School of Psychology at the University of Nottingham in the UK. Professor Scerif's research focuses on the development of attentional control and those underlying attentional difficulties.



Professor Vicki Anderson
Developmental Neuropsychologist, Murdoch Children's Research Institute (AUS)

Professor Anderson is a paediatric neuropsychologist at the Murdoch Children's Research Institute with over 30 years' experience. She is also the Director of Psychology at the Royal Children's Hospital. She is an NHMRC Senior Practitioner Fellow, and a Fellow of the Academy of Social Sciences Australia, the Australian Psychological Society and the Australasian Society for the Study of Brain Impairment. Professor Anderson's research is focused on improving our understanding of childhood acquired brain injury (e.g., traumatic brain injury, stroke, concussion), chronic illness (e.g., cystic fibrosis, cancer, chronic fatigue) and neurodevelopmental disorders (e.g., ADHD, learning disability). Her team is internationally recognised for their longitudinal work covering a range of modalities including neuroimaging, cognitive, social and behavioural outcomes, as well as psychological interventions for these children and their families.



Dr Jane Roberts
Developmental & Educational Psychologist, University of South Carolina (USA)

Dr Roberts is an educational and developmental psychologist at the University of South Carolina. She previously worked at the FPG Child Development Institute at the University of North Carolina. Her work focuses on understanding the biological mechanisms that underlie cognitive and behavioural functioning in children and adults with neurodevelopmental disorders such as autism, fragile X syndrome, and AD/HD.



AVEXA



Partners



MONASH University





Contact

Iain Kirkwood

Executive Chairman

M: +61 408 473 496

Peter Taylor

Investor/Media Relations

M: +61 412 036 231

Stefi Trenberth

Investor/Media Relations

M: +61 427 183 051

